Donors Must Continue Funding R&D To Bring New Global Health Technologies To Patients
In this post in the Hill’s “Congress Blog,” Kaitlin Christenson, the coalition director of the Global Health Technologies Coalition; Jim Connolly, president and CEO of Aeras; and Mel Spigelman, president and CEO of the TB Alliance, respond to a recently released G-FINDER report that shows “overall global investment in the research and development (R&D) of [new global health technologies] has declined for the first time since 2007, when the tracking of such funding began,” writing, “This decline is especially troubling given that there are more than 100 products in [the Product Development Partnerships’ (PDPs)] pipelines.”
The authors discuss the role of the private sector in investing in and supporting global health R&D and changes in the funding landscape as a result of the global financial crisis, and conclude, “We have made huge progress over the last decade but will not reach the finish line without urgent action. … High-income countries should view these findings as a wake-up call and work to put product development for diseases of poverty back on track. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients. Donors must commit to take them across the finish line or lose a historic opportunity to impact global health” (12/12).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.